ProCE Banner Activity

Nonmalignant Hematologic Disorders at ASH 2020: Our Choices for Most Notable Studies

Clinical Thought
In this commentary, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, share their top choices of new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.

Released: February 24, 2021

Expiration: February 23, 2022

No longer available for credit.

Share

Faculty

Mark A. Schroeder

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Sujit Sheth

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Mark A. Schroeder, MD, has disclosed that he has received consulting fees from GlaxoSmithKline, Janssen, and Sanofi Genzyme.

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Agios, Bristol-Myers Squibb/Celgene, Bluebird bio and CRISPR/Vertex and funds for research support from Bristol-Myers Squibb/Celgene, DisperSol, and La Jolla.